Imperial College London
Portrait Picture

DrLouisePaterson

Faculty of Medicine, Department of Brain Sciences

Advanced Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 7028l.paterson

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{McGonigle:2016:10.1177/0269881116668592,
author = {McGonigle, J and Murphy, A and Paterson, LM and Reed, LJ and Nestor, L and Nash, J and Elliott, R and Ersche, KD and Flechais, RS and Newbould, R and Orban, C and Smith, DG and Taylor, EM and Waldman, AD and Robbins, TW and Deakin, JW and Nutt, DJ and Lingford-Hughes, AR and Suckling, J and ICCAM, Platform},
doi = {10.1177/0269881116668592},
journal = {Journal of Psychopharmacology},
pages = {3--16},
title = {The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description},
url = {http://dx.doi.org/10.1177/0269881116668592},
volume = {31},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - OBJECTIVES: We aimed to set up a robust multi-centre clinical fMRI and neuropsychological platform to investigate the neuropharmacology of brain processes relevant to addiction - reward, impulsivity and emotional reactivity. Here we provide an overview of the fMRI battery, carried out across three centres, characterizing neuronal response to the tasks, along with exploring inter-centre differences in healthy participants. EXPERIMENTAL DESIGN: Three fMRI tasks were used: monetary incentive delay to probe reward sensitivity, go/no-go to probe impulsivity and an evocative images task to probe emotional reactivity. A coordinate-based activation likelihood estimation (ALE) meta-analysis was carried out for the reward and impulsivity tasks to help establish region of interest (ROI) placement. A group of healthy participants was recruited from across three centres (total n=43) to investigate inter-centre differences. PRINCIPLE OBSERVATIONS: The pattern of response observed for each of the three tasks was consistent with previous studies using similar paradigms. At the whole brain level, significant differences were not observed between centres for any task. CONCLUSIONS: In developing this platform we successfully integrated neuroimaging data from three centres, adapted validated tasks and applied whole brain and ROI approaches to explore and demonstrate their consistency across centres.
AU  - McGonigle,J
AU  - Murphy,A
AU  - Paterson,LM
AU  - Reed,LJ
AU  - Nestor,L
AU  - Nash,J
AU  - Elliott,R
AU  - Ersche,KD
AU  - Flechais,RS
AU  - Newbould,R
AU  - Orban,C
AU  - Smith,DG
AU  - Taylor,EM
AU  - Waldman,AD
AU  - Robbins,TW
AU  - Deakin,JW
AU  - Nutt,DJ
AU  - Lingford-Hughes,AR
AU  - Suckling,J
AU  - ICCAM,Platform
DO  - 10.1177/0269881116668592
EP  - 16
PY  - 2016///
SN  - 1461-7285
SP  - 3
TI  - The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description
T2  - Journal of Psychopharmacology
UR  - http://dx.doi.org/10.1177/0269881116668592
UR  - http://hdl.handle.net/10044/1/41444
VL  - 31
ER  -
Download